Mumbai-based gut health startup The Good Bug has raised ₹100 crore (approximately $12 million) in a Series B funding round led by Susquehanna Asia Venture Capital, the venture arm of Susquehanna International Group. Existing investor Fireside Ventures also participated in the round.
Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan.V, The Good Bug focuses on probiotic and gut-centric health products aimed at improving digestion, immunity, and metabolic health. The startup plans to utilize the fresh capital to enhance research and development in microbiome science, scale up clinical trials, expand its distribution network, and strengthen brand awareness among consumers and healthcare professionals.
In April, the company launched Metabolically Lean, a GLP-1-based formulation touted as a natural, non-invasive alternative to weight-loss drugs like Ozempic and Mounjaro. The product is designed to naturally elevate GLP-1 levels to suppress appetite and support metabolic function.
As India&rsquo;s nutraceuticals market grows, The Good Bug is positioning itself to lead in the wellness and gut health segments with a strong product pipeline and strategic growth roadmap.
&nbsp;
Source : startupro.in

Mumbai-based gut health startup The Good Bug has raised ₹100 crore (approximately $12 million) in a Series B funding round led by Susquehanna Asia Venture Capital, the venture arm of Susquehanna International Group. Existing investor Fireside Ventures also participated in the round.

The Good Bug Raises ₹100 Cr in Series B to Accelerate Gut Health Innovation and Expansion